Literature DB >> 1725315

Localization of endothelin-1 (ET-1), ET-2, and ET-3, mouse VIC, and sarafotoxin S6b binding sites in mammalian heart and kidney.

A P Davenport1, A J Morton, M J Brown.   

Abstract

Quantitative in vitro receptor autoradiography was used to identify and compare binding sites for endothelin-1 (ET-1), ET-2, and ET-3, mouse vasoactive intestinal contractor (VIC), and sarafotoxin S6b in human, porcine, and rat cardiac and renal tissues. In the rat kidney, the highest densities of binding sites for all five labeled peptides were present in the glomeruli, with lower levels in the papilla, cortex, and inner band of the medulla. A similar pattern was found in porcine and human kidney except that no discrete glomerular binding could be detected. In the heart, higher densities were detected in the atria compared to the ventricle. Although the pattern of binding in cardiac and renal tissue was similar for all four labeled ET isoforms, nonspecific binding was consistently higher with ET-3, resulting in lower levels of specific binding. These results suggest that these peptides could be acting via the same population of binding sites, but multiple receptor subtypes may exist that differ in their rank order of affinity for the ET isoforms and sarafotoxin S6b, as proposed in other tissues.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1725315     DOI: 10.1097/00005344-199100177-00042

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

Authors:  A P Davenport; R E Kuc; S L Hoskins; F E Karet; F Fitzgerald
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

2.  Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart.

Authors:  M G Peter; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

3.  Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart.

Authors:  M G Peter; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

4.  Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments.

Authors:  J J Maguire; R E Kuc; B A Rous; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

5.  Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.

Authors:  A P Davenport; G O'Reilly; R E Kuc
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

6.  Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo.

Authors:  Peter Johnström; Tim D Fryer; Hugh K Richards; Neil G Harris; Olivier Barret; John C Clark; John D Pickard; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

Review 7.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.